Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $0.16 and traded as low as $0.1550. Northwest Biotherapeutics shares last traded at $0.1565, with a volume of 4,713,982 shares.
Northwest Biotherapeutics Stock Performance
The company has a market cap of $285.45 million, a PE ratio of -5.22 and a beta of -0.60. The company’s 50 day moving average price is $0.16 and its 200-day moving average price is $0.19.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The biotechnology company reported ($0.02) EPS for the quarter. The company had revenue of $0.88 million during the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Northwest Biotherapeutics stock. Compass Financial Management LLC purchased a new position in shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned 0.07% of Northwest Biotherapeutics as of its most recent filing with the SEC. 0.04% of the stock is currently owned by hedge funds and other institutional investors.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company developing immunotherapies for cancer, with a focus on treatments made from a patient’s own immune cells. Its platform uses dendritic cells, which can help the immune system recognize and respond to cancer. The company’s lead product candidate, DCVax-L, is a personalized dendritic-cell therapy being developed for glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational therapy designed to be injected into tumors.
Further Reading
- Five stocks we like better than Northwest Biotherapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
